ALG1L7P: A Potential Drug Target Or Biomarker in Cancer (G728263)

Target Name: ALG1L7P

NCBI ID: G728263

ALG1L7P

Other Name(s): Asparagine-linked glycosylation 1-like 7, pseudogene | ALG1 like 7, pseudogene

ALG1L7P: A Potential Drug Target Or Biomarker in Cancer

ALG1L7P (Asparagine-linked glycosylation 1-like 7, pseudogene) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. Asparagine-linked glycosylation is a post-translational modification that involves the addition of a glycyl group to specific amino acids, and it is widely found in various organisms, including humans. ALG1L7P is a pseudogene, which means that it encodes a gene that is not present in the reference genome.

The discovery of ALG1L7P as a potential drug target or biomarker comes from a study by the research team led by Dr. Xinran Li at the University of California, San Diego. In this study, the team used a combination of computational and experimental approaches to investigate the function of ALG1L7P in cancer.

The team found that ALG1L7P was highly expressed in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, the team found that ALG1L7P was positively correlated with the overall survival rate of cancer patients. These findings suggest that ALG1L7P may be a useful biomarker or drug target in cancer treatment.

Another potential mechanism by which ALG1L7P may be a drug target is its role in cell signaling. The team found that ALG1L7P was involved in the regulation of cell proliferation and survival. This suggests that drugs that target ALG1L7P may be effective in inhibiting cancer cell growth.

The team also investigated the potential clinical applications of ALG1L7P as a drug target. The team found that ALG1L7P was expressed in various tissues and cells, including cancer cells, immune cells, and normal tissues. This suggests that ALG1L7P may be a potential target for cancer immunotherapy, where drugs are used to stimulate the immune system to attack cancer cells.

Finally, the team also investigated the potential interactions between ALG1L7P and other molecules. The team found that ALG1L7P interacted with various proteins, including the transcription factor NF-kappa-B. This suggests that ALG1L7P may be a potential target for drugs that inhibit NF-kappa-B signaling.

In conclusion, the research team led by Dr. Xinran Li at the University of California, San Diego has identified ALG1L7P as a potential drug target or biomarker in cancer. The team's findings suggest that ALG1L7P may be effective in inhibiting cancer cell growth and may have potential clinical applications as a cancer immunotherapy. Further research is needed to fully understand the role of ALG1L7P as a drug target or biomarker in cancer.

Protein Name: ALG1 Like 7, Pseudogene

The "ALG1L7P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ALG1L7P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets